NetworkNewsBreaks – BioDelivery Sciences (NASDAQ: BDSI) Shares Higher on New Patents Protecting BELBUCA®, BUNAVAIL® and ONSOLIS®

BioDelivery Sciences (NASDAQ: BDSI) shares are up 7% after the company this morning said that it has received two new patents further strengthening BDSI’s overall intellectual property position. The new patents protect all three of its FDA-approved products: BELBUCA® buccal film, BUNAVAIL® buccal film, and ONSOLIS®. One patent covers the composition of the BioErodible MucoAdhesive (BEMA®) drug delivery technology, which provides additional patent coverage for BELBUCA and BUNAVAIL to July 2027 and will be listed in the Orange Book. The second patent, also to be listed in the Orange Book, extends protection on ONSOLIS from January 2020 to July 2027. Per the company’s licensing agreement with Collegium Pharmaceutical regarding ONSOLIS, the patent grant will result in a $3 million milestone payment to BDSI following FDA approval of a supplemental application supporting the new manufacturer for ONSOLIS. The company also expects a $4 million milestone payment for the first commercial sale of ONSOLIS in the first half of 2018.

To view the full press release, visit: http://nnw.fm/2F0cu

About BioDelivery Sciences International

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine. BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs. BDSI’s development strategy focuses on the utilization of the FDA’s 505(b)(2) approval process. This regulatory pathway creates the potential for more timely and efficient approval of new formulations of previously approved therapeutics. BDSI’s marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain, painful diabetic neuropathy and opioid dependence. BDSI’s headquarters is in Raleigh, North Carolina. For more information, please visit www.bdsi.com.

About NetworkNewsBreak

NetworkNewsBreak (NNB) provides a rapid summary of corporate news that caught the attention of NetworkNewsWire (NNW). NNB keeps you up-to-date on active US Public Companies complementary to NNW’s broader scope as a provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s